If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Mahesh Patel Biography and Net Worth

CEO of Lipocine

Dr. Mahesh V. Patel has more than 20 years of technology and product development experience in the area of drug discovery support, drug delivery and product line extensions. Prior to co-founding Lipocine in 1997, Dr. Patel led drug delivery research and development at Pharmacia and Upjohn in Kalamazoo, MI. He received his MS in Physical Pharmacy at the University of Cincinnati and his PhD in Pharmaceutics from the University of Utah. His areas of expertise include strategic planning, technology assessment/development, technical management and product research and development.

What is Mahesh V. Patel's net worth?: The estimated net worth of Mahesh V. Patel is at least $533,800.43 as of March 24th, 2023. Dr. Patel owns 1,678,090 shares of Lipocine stock worth more than $533,800 as of March 31st. This net worth evaluation does not reflect any other assets that Dr. Patel may own. Learn More about Mahesh V. Patel's net worth.
What is Mahesh V. Patel's salary?: As the CEO of Lipocine Inc., Dr. Patel earned a total compensation package of $994,403.00 in 2020. Dr. Patel earned a salary of $456,932.00, options awards of $214,266.00, non-equity compensation of $308,429.00, and other compensation of $14,775.00. Learn More on Mahesh V. Patel's salary.
How do I contact Mahesh V. Patel?: The corporate mailing address for Dr. Patel and other Lipocine executives is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. Lipocine can also be reached via phone at (801) 994-7383 and via email at [email protected] Learn More on Mahesh V. Patel's contact information.
Has Mahesh V. Patel been buying or selling shares of Lipocine?: In the last ninety days, Mahesh V. Patel has bought $64,500.00 in shares of Lipocine stock. Most recently, on Friday, March 24th, Mahesh V. Patel bought 150,000 shares of Lipocine stock. The stock was acquired at an average cost of $0.32 per share, with a total value of $48,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,678,090 shares of the company's stock, valued at $536,988.80. Learn More on Mahesh V. Patel's trading history.
Are insiders buying or selling shares of Lipocine?: In the last year, Lipocine insiders bought shares 7 times. They purchased a total of 388,239 shares worth more than $166,327.33. The most recent insider tranaction occured on March, 24th when CEO Mahesh V Patel bought 150,000 shares worth more than $48,000.00. Insiders at Lipocine own 5.2% of the company. Learn More about insider trades at Lipocine.
Information on this page was last updated on 3/24/2023.

Mahesh V. Patel Insider Trading History at Lipocine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/24/2023	Buy	150,000	$0.32	$48,000.00	1,678,090
3/17/2023	Buy	50,000	$0.33	$16,500.00	1,528,090
9/27/2022	Buy	100,000	$0.41	$41,000.00	1,403,090
5/16/2022	Buy	50,000	$0.77	$38,500.00	1,303,090
11/18/2021	Buy	25,000	$1.09	$27,250.00
12/16/2020	Sell	15,000	$1.35	$20,250.00
12/4/2020	Sell	43,500	$1.57	$68,295.00	1,118,612
12/31/2019	Buy	40,000	$0.42	$16,800.00
12/10/2019	Buy	25,000	$0.40	$10,000.00	933,612
12/4/2019	Sell	43,500	$0.39	$16,965.00
11/26/2019	Buy	25,000	$0.43	$10,750.00	783,384
11/18/2019	Buy	50,000	$0.40	$20,000.00	737,043
12/29/2017	Sell	6,000	$3.48	$20,880.00
12/29/2017	Sell	6,000	$3.48	$20,880.00	728,112
9/30/2015	Buy	4,000	$11.84	$47,360.00	887,632
11/25/2014	Buy	2,000	$5.10	$10,200.00
11/24/2014	Buy	2,000	$5.45	$10,900.00
11/14/2014	Buy	2,000	$5.06	$10,120.00
11/13/2014	Buy	2,000	$5.05	$10,100.00

Mahesh V. Patel Buying and Selling Activity at Lipocine

Lipocine Company Overview

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Today's Range

Now: $0.32

$0.31

$0.33

50 Day Range

MA: $0.44

$0.30

$0.55

2 Week Range

Now: $0.32

$0.27

$1.64

Volume

89,619 shs

Average Volume

172,670 shs

Market Capitalization

$28.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

The Safest Option in Trades!

From Tradewins | Ad

Click here now!